Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ASCENDIS PHARMA A/S

(ASND)
  Report
Real-time Estimate Cboe BZX  -  12:16 2022-12-01 pm EST
121.83 USD   -1.00%
11/30European Equities Nudge Higher on Slightly Lower Euro Area Inflation
MT
11/22Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
AQ
11/16European Equities Flat in Choppy Trade Wednesday as Geopolitical Tensions Weigh
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Wells Fargo Adjusts Ascendis Pharma Price Target to $172 From $167, Maintains Overweight Rating

09/22/2022 | 09:34am EST


ę MT Newswires 2022
All news about ASCENDIS PHARMA A/S
11/30European Equities Nudge Higher on Slightly Lower Euro Area Inflation
MT
11/22Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
AQ
11/16European Equities Flat in Choppy Trade Wednesday as Geopolitical Tensions Weigh
MT
11/15Morgan Stanley Adjusts Price Target on Ascendis Pharma to $148 From $146, Maintains Ove..
MT
11/15Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines A..
AQ
11/14European ADRs Continue to Trend Higher in Monday Trading
MT
11/14Ascendis Pharma Submits Marketing Authorization Application in EU for Hypoparathyroidis..
MT
11/14Dose Escalation Data from transcendIT-101 Ascendis Pharma's Phase 1/2 Trial of TransCon..
AQ
11/14Once-Weekly TransCon CNP Achieved Primary Efficacy Objective, with Superiority at 100 -..
AQ
11/14Transcript : Ascendis Pharma A/S - Special Call
CI
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
Financials
Sales 2022 47,4 M 48,9 M 48,9 M
Net income 2022 -528 M -544 M -544 M
Net cash 2022 513 M 530 M 530 M
P/E ratio 2022 -12,5x
Yield 2022 -
Capitalization 6 668 M 6 876 M 6 876 M
EV / Sales 2022 130x
EV / Sales 2023 44,0x
Nbr of Employees 639
Free-Float 10,3%
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 119,33 €
Average target price 154,17 €
Spread / Average Target 29,2%
EPS Revisions
Managers and Directors
Jan M°ller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Birgitte Volck SVP, Head-Clinical Development & Medical Affairs
Kennett Sprog°e Senior Vice President, Head-Innovation & Research
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S-8.53%6 876
VERTEX PHARMACEUTICALS44.08%81 217
REGENERON PHARMACEUTICALS, INC.16.56%80 283
BIONTECH SE-35.21%40 589
WUXI APPTEC CO., LTD.-34.22%32 137
GENMAB A/S24.30%29 594